🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
542,50 USD
Máx. histórico
558,88
6 días
Split 2:1 del 24/08/2000
Caída desde máximo
-2,93%
Rango 52 semanas
406,67 – 568,67
Variación hoy
-1,19%
Cierre anterior
549,04
Rango de hoy
540,02 – 557,85
Volumen hoy
2.467.517
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 34,91 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 1 día
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 12/01/2010 | 41,87 | 42,61 | 41,11 | 41,79 | -0,10% | 3,58% | 2.179.400 |
| 11/01/2010 | 40,81 | 42,13 | 40,50 | 41,83 | +2,85% | 3,99% | 2.193.100 |
| 08/01/2010 | 41,45 | 41,50 | 40,41 | 40,67 | -2,00% | 2,63% | 3.687.900 |
| 07/01/2010 | 42,00 | 42,49 | 41,44 | 41,50 | -1,26% | 2,50% | 1.873.200 |
| 06/01/2010 | 42,51 | 42,87 | 41,86 | 42,03 | -1,75% | 2,38% | 2.313.700 |
| 05/01/2010 | 43,06 | 43,35 | 42,50 | 42,78 | -3,30% | 1,97% | 2.456.500 |
| 04/01/2010 | 42,85 | 44,24 | 42,80 | 44,24 | +3,24% | 3,36% | 1.744.900 |
| 31/12/2009 | 43,49 | 43,58 | 42,81 | 42,85 | -1,61% | 1,77% | 864.500 |
| 30/12/2009 | 43,53 | 44,04 | 43,38 | 43,55 | +0,46% | 1,52% | 921.500 |
| 29/12/2009 | 43,40 | 43,53 | 43,09 | 43,35 | +0,30% | 1,01% | 1.081.800 |
| 28/12/2009 | 43,00 | 43,53 | 42,92 | 43,22 | +0,42% | 1,42% | 742.100 |
| 24/12/2009 | 42,67 | 43,04 | 42,35 | 43,04 | +0,91% | 1,62% | 283.100 |
| 23/12/2009 | 43,01 | 43,16 | 42,55 | 42,65 | -0,58% | 1,42% | 1.174.300 |
| 22/12/2009 | 42,15 | 43,02 | 42,02 | 42,90 | +1,78% | 2,37% | 1.471.100 |
| 21/12/2009 | 42,30 | 42,72 | 41,74 | 42,15 | -0,45% | 2,32% | 2.016.600 |
| 18/12/2009 | 41,10 | 42,35 | 41,00 | 42,34 | +2,94% | 3,28% | 5.747.400 |
| 17/12/2009 | 42,27 | 42,61 | 41,13 | 41,13 | -3,25% | 3,50% | 2.574.300 |
| 16/12/2009 | 41,62 | 42,52 | 41,31 | 42,51 | +2,29% | 2,91% | 2.827.200 |
| 15/12/2009 | 40,37 | 41,57 | 40,22 | 41,56 | +2,36% | 3,34% | 3.133.000 |
| 14/12/2009 | 39,76 | 40,64 | 39,72 | 40,60 | +1,75% | 2,31% | 1.432.300 |
| 11/12/2009 | 40,39 | 40,59 | 39,40 | 39,90 | -0,97% | 2,95% | 1.349.300 |
| 10/12/2009 | 40,16 | 40,62 | 39,80 | 40,29 | +0,27% | 2,04% | 1.454.000 |
| 09/12/2009 | 39,64 | 40,28 | 39,13 | 40,18 | +0,90% | 2,90% | 1.868.100 |
| 08/12/2009 | 39,00 | 39,85 | 38,67 | 39,82 | +1,61% | 3,03% | 1.725.200 |
| 07/12/2009 | 39,70 | 39,80 | 38,89 | 39,19 | -1,11% | 2,29% | 1.299.800 |
| 04/12/2009 | 40,23 | 40,44 | 39,16 | 39,63 | -1,47% | 3,18% | 2.292.700 |
| 03/12/2009 | 39,98 | 40,39 | 38,97 | 40,22 | +1,85% | 3,55% | 7.632.200 |
| 02/12/2009 | 39,70 | 40,05 | 39,34 | 39,49 | -0,93% | 1,79% | 1.403.800 |
| 01/12/2009 | 39,06 | 40,20 | 38,82 | 39,86 | +2,68% | 3,53% | 1.781.900 |
| 30/11/2009 | 39,00 | 39,12 | 38,42 | 38,82 | -0,46% | 1,79% | 1.596.200 |